Drug Profile


Alternative Names: BIIB 050; KNS-760704; RPPX

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Virginia
  • Developer Biogen Idec; Knopp Biosciences; National Institute of Allergy and Infectious Diseases
  • Class Antiparkinsonians; Benzothiazoles; Neuroprotectants; Small molecules
  • Mechanism of Action Antioxidants; Apoptosis inhibitors; Dopamine receptor agonists; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis; Hypereosinophilic syndrome

Most Recent Events

  • 22 Apr 2017 Interim pharmacodynamic data from a phase III trial in Amyotrophic lateral sclerosis presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 07 Mar 2017 Efficacy data from a phase II trial in Hypereosinophilic syndrome released by Knopp Biosciences
  • 07 Mar 2017 Efficacy data from a phase III trial in Amyotrophic lateral sclerosis released by Knopp Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top